{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:01:55Z","timestamp":1778799715297,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Calcitonin (Ctn) is widely used as a marker in the diagnosis, prognosis, and postoperative follow-up of patients with medullary thyroid carcinoma (MTC). The prognostic value of postoperative calcitonin-to-preoperative calcitonin ratio (CR), reflecting the change in Ctn level of response to initial treatment, remains uncertain in long-term disease outcomes. This study aims to determine the cut-off value of CR for predicting structural recurrence and assess the prognostic role of CR in patients with MTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed patients with MTC in Sun Yat-sen University Cancer Center (SYSUCC) between 2000 and 2022. CR is defined as the ratio of postoperative Ctn level on the day of discharge divided by preoperative Ctn level. In order to determine the optimal cut-off value of CR, the receiver operating characteristic (ROC) analysis was performed. We evaluate the effect of CR on recurrence-free survival (RFS) by using the Kaplan-Meier method and Cox regression analysis. Then, a nomogram based on CR was constructed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 112 sporadic MTC patients were included in this study. The optimal cut-off value of CR that predicted disease recurrence was 0.125. Patients with CR\u22650.125 showed significantly worse RFS than patients with CR &amp;lt;0.125, respectively (3-years RFS rate of 63.1 vs. 94.7%, 5-years RFS rate of 50.7 vs. 90.3%, P &amp;lt; 0.001). In the multivariate analysis, CR was the strongest independent predictor of structural recurrence (HR: 5.050, 95% CI: 2.247\u201311.349, <jats:italic>P &amp;lt;<\/jats:italic>0.001). Tumor size (HR: 1.321, 95% CI: 1.010\u20131.726, <jats:italic>P<\/jats:italic> =0.042), multifocality (HR: 2.258, 95% CI: 1.008\u20135.058, <jats:italic>P<\/jats:italic> =0.048) and metastasized lymph nodes (HR: 3.793, 95% CI: 1.617\u20138.897, <jats:italic>P &amp;lt;<\/jats:italic>0.001) were also independent predictors of structural recurrence. The uncorrected concordance index (c-index) of the nomogram was 0.827 (95% CI, 0.729-0.925) for RFS, and bias-corrected c-index were similar. As compared to TNM stage, the nomogram based on CR provided better discrimination accuracy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We demonstrate that CR is a strong prognostic marker to predict structural recurrence in patients with sporadic MTC. The nomogram incorporating CR provided useful prediction of RFS for patients with sporadic MTC to provide personalized treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1094242","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T07:31:11Z","timestamp":1671175871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Zan","family":"Jiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.19.2.114","article-title":"Histogenesis of medullary carcinoma of the thyroid","volume":"19","author":"Williams","year":"1966","journal-title":"J Clin Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196808082790602","article-title":"Medullary carcinoma of the thyroid gland. studies of thyrocalcitonin in plasma and tumor extracts","volume":"279","author":"Tashjian","year":"1968","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0506","article-title":"Genotype and phenotype landscape of Men2 in 554 medullary thyroid cancer patients: The brasmen study","volume":"8","author":"Maciel","year":"2019","journal-title":"Endocr Connect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2265.2008.03229.x","article-title":"Long-term prognosis of medullary thyroid carcinoma","volume":"69","author":"Rendl","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.118380a","article-title":"Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas","volume":"130","author":"Weber","year":"2001","journal-title":"Surgery"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/PAP.0000000000000004","article-title":"Update on the cytologic and molecular features of medullary thyroid carcinoma","volume":"21","author":"Pusztaszeri","year":"2014","journal-title":"Adv Anat Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1590\/0004-2730000003427","article-title":"Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: Recommendations by the thyroid department of the Brazilian society of endocrinology and metabolism","volume":"58","author":"Maia","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000336977","article-title":"2012 European Thyroid association guidelines for metastatic medullary thyroid cancer","volume":"1","author":"Schlumberger","year":"2012","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0667","article-title":"Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times","volume":"158","author":"Laure Giraudet","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0217","article-title":"Tumor grade predicts for calcitonin doubling times and disease-specific outcomes after resection of medullary thyroid carcinoma","volume":"32","author":"Nigam","year":"2022","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0295","article-title":"An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: Results of a retrospective cohort study","author":"Duval","year":"2022","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0167","article-title":"Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades","volume":"31","author":"Kotwal","year":"2021","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11071","article-title":"Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer","volume":"106","author":"Machens","year":"2019","journal-title":"Br J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202202_28009","article-title":"Predictive factors for lymph node involvement in sporadic medullary thyroid microcarcinoma: A systematic review","volume":"26","author":"Scerrino","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0277","article-title":"Response to initial therapy predicts clinical outcomes in medullary thyroid cancer","volume":"25","author":"Lindsey","year":"2015","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.749973","article-title":"Prognostic value of preoperative serum calcitonin levels for predicting the recurrence of medullary thyroid carcinoma","volume":"12","author":"Park","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0428","article-title":"Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma","volume":"59","author":"Kratzsch","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: A structured meta-analysis","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-411","article-title":"Aurora kinases are expressed in medullary thyroid carcinoma (Mtc) and their inhibition suppresses in vitro growth and tumorigenicity of the mtc derived cell line tt","volume":"11","author":"Baldini","year":"2011","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12852","article-title":"Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: A Large-scale retrospective analysis over 30 years","volume":"84","author":"Jung","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/030089169408000205","article-title":"Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma","volume":"80","author":"Girelli","year":"1994","journal-title":"Tumori"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0110357","article-title":"Postoperative calcitonin study in medullary thyroid carcinoma","volume":"11","author":"Ismailov","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2011.09.043","article-title":"Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma","volume":"150","author":"Yip","year":"2011","journal-title":"Surgery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.2.6556","article-title":"Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. groupe d'etudes des tumeurs a calcitonine (Getc)","volume":"85","author":"Cohen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0849-6","article-title":"Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy","volume":"53","author":"Kwon","year":"2016","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","article-title":"Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging","volume":"49","author":"Tuttle","year":"2013","journal-title":"Oral Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4115-6","article-title":"Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ata guidelines","volume":"22","author":"Verbeek","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0079","article-title":"Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical Recurrence\/Persistent disease in medullary thyroid carcinoma","volume":"29","author":"Shi","year":"2019","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1507\/endocrj.EJ20-0025","article-title":"The revised clinical practice guidelines on the management of thyroid tumors by the Japan associations of endocrine surgeons: Core questions and recommendations for treatments of thyroid cancer","volume":"67","author":"Ito","year":"2020","journal-title":"Endocr J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0255","article-title":"Multifocality in sporadic medullary thyroid carcinoma: An international multicenter study","volume":"26","author":"Essig","year":"2016","journal-title":"Thyroid"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00104-013-2705-7","article-title":"[Surgery for benign goiter in Germany: Fewer operations, changed resectional strategy, fewer complications]","volume":"85","author":"Dralle","year":"2014","journal-title":"Chirurg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: More than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1094242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T07:31:15Z","timestamp":1671175875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1094242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":35,"alternative-id":["10.3389\/fendo.2022.1094242"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1094242","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"article-number":"1094242"}}